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Abstract
Background: Genome wide association studies have identified > 200 susceptibility loci accounting for much of the
heritability of multiple sclerosis (MS). Epstein-Barr virus (EBV), a memory B cell tropic virus, has been identified as
necessary but not sufficient for development of MS. The molecular and immunological basis for this has not been
established. Infected B cell proliferation is driven by signalling through the EBV produced cell surface protein LMP1,
a homologue of the MS risk gene CD40.
Methods: We have investigated transcriptomes of B cells and EBV-infected B cells at Latency III (LCLs) and identified
MS risk genes with altered expression on infection and with expression levels associated with the MS risk genotype
(LCLeQTLs). The association of LCLeQTL genomic burden with EBV phenotypes in vitro and in vivo was examined. The
risk genotype effect on LCL proliferation with CD40 stimulation was assessed.
Results: These LCLeQTL MS risk SNP:gene pairs (47 identified) were over-represented in genes dysregulated between B
and LCLs (p < 1.53 × 10−4), and as target loci of the EBV transcription factor EBNA2 (p < 3.17 × 10−16). Overall genetic
burden of LCLeQTLs was associated with some EBV phenotypes but not others. Stimulation of the CD40 pathway by
CD40L reduced LCL proliferation (p < 0.001), dependent on CD40 and TRAF3 MS risk genotypes. Both CD40 and TRAF3
risk SNPs are in binding sites for the EBV transcription factor EBNA2, with expression of each correlated with EBNA2
expression dependent on genotype.
Conclusions: These data indicate targeting EBV may be of therapeutic benefit in MS.
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Background
Epstein-Barr virus (EBV), a memory B cell tropic virus,
has been identified as necessary but not sufficient for de-
velopment of MS [1]. This implies it is necessary to initi-
ate pathogenesis, but the molecular and immunological
basis for this has not been established. Its potential
importance in pathogenesis has been highlighted by the
success of therapies removing memory B cells (antiCD20
monoclonal antibodies) and the failure of therapies
which increase them (antiTACI monoclonal antibodies)
[2]. Causality is also indicated from three large studies
using different approaches. From a large longitudinal
study, adults without EBV antibodies who later devel-
oped MS also were infected by EBV [3]. The risk of
developing MS for those with the HLA-DRB1*1501
allele and for EBV infection is higher for the combin-
ation than due to each factor independently, suggesting
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an interaction and causality [4, 5]. Finally, the time to
developing MS is shorter for those with late EBV infec-
tion than for those with early EBV infection, consistent
with infection affecting development of disease [6].
First infection with EBV at a later age confers greater
risk of developing MS than early infection [7]. In
addition, association studies indicate higher EBV loads
for those with MS compared to controls [8] and
decreased T cell response to EBV antigen on therapy in
those with a clinical response, potentially reducing epi-
tope spreading and autoinflammation [9], suggesting an
effect on disease progression. Due to its ability to
immortalise B cells, EBV can cause a number of malig-
nancies [10], notably nasopharyngeal cancer and Hodg-
kin’s lymphoma. In immunocompromised individuals,
such as those receiving transplants, unrestrained EBV
infection can be fatal. MS risk SNPs are over-repre-
sented as target sites for the EBV transcription factor
EBNA2 [11], especially in conjunction with the vitamin
D receptor binding sites [12]. Collectively, these data in-
dicate this near-ubiquitous virus is usually controlled by
a sustained immune response and are consistent with
the hypothesis that failure of EBV control can induce
disease, including MS. Moreover, EBV control may con-
tinue to be impaired and worsen in established MS.
With increasing disease duration, EBV-specific T cells
progressively decline, consistent with T cell exhaustion
and inversely proportional to anti-EBNA-1 titres [13].
There is a higher incidence of spontaneous transforming
events in long-term culture of MS B cells [14], together
supporting the existence of a higher proportion of la-
tently EBV-infected B cells in MS.
Where EBV causes tumours, symptoms of infection, or
uncontrolled lymphocyte proliferation, possible treat-
ments include antiCD20 antibodies to remove the host
target cell, anti EBV T cells from tissue banks, or genetic
manipulation of anti EBV T cells [15]. Vaccines to spe-
cifically boost immune response are in development
[15]. To promote further development of these ap-
proaches and to identify novel ones, a better under-
standing of immune evasion by EBV is needed. The
genetic variation that increases risk of MS may indicate
molecular pathways controlling EBV and so targets for
improved therapy.
More than 200 gene loci have been associated with
MS using genome wide association studies (GWAS)
[16]. Their effect is mainly on gene expression. EBV has
four transcriptomes corresponding to three latency
phases and a lytic phase. Latency III phase is the major
target of the four phases for the immune response in
chronic disease [17]. To find risk genes potentially af-
fecting control of EBV infection, firstly, we identified MS
risk genes expressed differently in B cells and
EBV-infected B cells at Latency III (called LCLs, for
lymphoblastoid cell lines) using RNAseq. Second, we
used in silico data on the association of genotypes with
expression in whole blood and LCLs, to identify
LCLeQTLs. We then retested the SNP associations with
expression in independent cohorts of LCLs and B cells.
Further, we sought evidence of EBV regulation of these
LCLeQTLs using pathway analysis and analysis of EBV
transcription factor binding sites near LCLeQTLs.
Lastly, we assessed the effect of genetic burden of
LCLeQTLs on EBV phenotypes in vitro and in vivo.
Many of the LCLeQTL genes mapped on to the
LMP1/LMP2 signalling pathway. For one of the first
genes to be identified as an MS risk factor using GWAS,
CD40 [18], a T cell activation gene, the protective allele
was shown to have higher expression [19]. This is
counter-intuitive, since T cell activation is thought to
promote MS risk. A potential explanation for this
paradox is that higher expression of CD40 reduces sig-
nalling through the EBV protein LMP1, a homologue of
CD40, inhibiting EBV survival in B cells. This could
occur via competition for intracellular signalling mole-
cules shared between these pathways. Increased
cross-linking of CD40 has been shown to inhibit LCL
proliferation [20, 21]. Here we have investigated CD40L
inhibition of LCL proliferation and the effect of the
CD40 risk genotype and that of another MS risk gene,
TRAF3, a ligand for both CD40 and LMP1.
These data provide genetic support for a facilitative role
of EBV infection in MS, but do not prove it. They indicate
molecular processes important in regulating LCL prolifer-
ation, and so molecular targets for control of EBV infec-
tion and potentially reducing MS progression.
Methods
Samples
All blood samples were collected from healthy controls
with informed consent (Westmead Hospital Human Re-
search Ethics Committee Approval 1425). B lymphocytes
were purified by immunomagnetic human B cell enrich-
ment Kit (Stem Cell Technologies) according to the
manufacturer’s instructions. For LCL generation, fresh
or frozen PBMCs from the B cell donors were infected
with supernatant from B95.8 producer cell line for 1 h at
37 °C. Cells were then suspended in complete medium,
consisting of RPMI-1640 (Lonza) supplemented with
10% fetal bovine serum (FBS, Sigma Aldrich), 2 mM
L-glutamine (Life Technologies), 50 units per ml penicil-
lin/50 g per ml streptomycin (Life Technologies) plus
2 μg/ml of cyclosporin A (Sigma Aldrich) and plated at
2.5 × 106 or 5 × 106 cells/well in 48-well plates. Cells
were fed weekly, expanded into 25-cm2 flask. LCLs were
cryopreserved in 10% DMSO (MP Biomedical) 50% FBS
and RPMI.
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RNAseq
Global gene expression profiling using RNAseq was car-
ried out for n = 5 LCL and CD19+ B cells (matching do-
nors). Total RNA was first isolated using the RNeasy
Mini Kit (Qiagen) before RNAseq library preparation
using the TruSeqV2 Library Preparation kit (Illumina).
The indexed libraries were pooled 10 plex, and 50 bp
single-end reads were sequenced on the HiSeq 2500
(Illumina). Reads were assessed for quality using FastQC,
aligned to hg19 using TopHat2 [22], and summarised to
RPKM gene level expression using SAMmate [23]. An
average of 18 million mapped reads was obtained for
each sample at an overall alignment rate of 80.5%.
Differentially expressed genes were calculated using EdgeR
[24]. A cut-off of 1% false discovery rate was selected to
select differentially expressed genes, see Additional file 1:
Table S1. The raw and processed sequencing data gener-
ated have been submitted to the NCBI Gene Expression
Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) under
accession number GSE126379 [25].
GTEx eQTL in LCL and WB
The rAggr website (www.raggr.usc.edu) was used to pre-
pare the variant call format (VCF) for all 201 MS risk
SNPs from rs ID and genomic coordinates (187 SNPs
were located). eQTL data for 186 of these SNPs was
available from the GTEx dataset [26] for both LCL and
whole blood (WB). We filtered proximal genes from all
eQTL data associated with MS risk SNPs in LCL and
WB (Additional file 2: Figure S1) and merged the two
datasets as a final SNP:gene table to compare the geno-
type effect of each MS risk SNPs in LCL and WB. The
effect of risk allele relative to protective allele based on
the slope data was then extracted. We identified the
SNP:gene eQTL pairs with higher association in LCL
than WB based on the p value being less than 0.05 in
LCL, and of a lower rank in p value ranking system for
SNP:gene list in LCL than WB. Also, of the genes with a
p < 0.05 in LCLs, those with a reverse slope between
LCLs and WB were included. The set of MS risk SNPs,
all eQTL data for MS risk SNPs in LCL and WB, eQTL
data for proximal genes of MS risk SNPs and SNP:gene
pairs eQTL with higher association in LCL than WB are
reported in Additional file 1: Table S2–S6, and the de-
tailed workflow is in Additional file 2: Figure S2.
Gene expression analysis of activated B cells, B cells and
LCLs
The normalizied microarray gene expression data for
LCL, activated B cells and B cells (n = 3 matching do-
nors) were obtained from [27, 28]. Differentially
expressed genes for activated B cell vs B cell and LCL vs
B cell were calculated using the GEO2R web tool on
NCBI Gene Expression Omnibus (GEO; http://www.
ncbi.nlm.nih.gov/geo/).
Pathway analysis
MetaCore by Clarivate Analytics (https://clarivate.com/
products/metacore) was used to undertake pathway ana-
lysis of proximal genes for: (I) EBV transcription factors
binding to MS risk SNPs, (II) SNP:gene eQTL pairs with
higher association in LCL rather than WB, (III) all prox-
imal SNP:gene eQTL pairs in LCL, all proximal
SNP:gene eQTL pairs in WB and (IV) all proximal
SNP:gene eQTL pairs in WB without SNP:gene eQTL
pairs with higher association in LCL rather than WB.
EBV transcription factors/MS risk SNPs
EBV transcription factors binding peak ChIP-seq data
were extracted from the Regulatory Element Local Inter-
section (RELI) tool [11, 29]. Genomic coordinates of
ChIP-seq data for BZLF1, EBNA2, EBNA3c, EBNA1 and
EBNALP EBV transcription factors in LCL were pre-
pared as a BED file. Bedtools v2.26.0 software was used
to identify the overlap between MS risk SNPs, SNPs in
LD with them, and EBV transcription factor binding
peaks (Additional file 1: Table S7). All steps of this work-
flow are illustrated in Additional file 2: Figure S3.
Genetic burden and EBV phenotypes in vitro and in vivo
The genetic burden (total amount of risk alleles) of MS
risk SNPs was calculated by assuming 2 score for risk
genotype, 1 score for heterozygous genotype and 0 score
for protective genotype and summing up the scores of
all MS risk SNPs for each LCL sample. Genotype data
for MS risk SNPs was extracted for 176 CEU individuals
from 1000 Genome and HAPMAP 3 projects LCL sam-
ples [30]. Intrinsic growth rate was available for LCLs
from 92 CEU individuals [31]. The gene expression data
for EBV from the same LCL samples was available on
the EBV Portal [32, 33]. Also, estimated EBV DNA copy
number in the same LCL samples was obtained [34].
Spearman’s rank correlation coefficient was used for
testing the significance of correlations. Linear regression
was used for testing the significance of correlation be-
tween genetic burden and EBV phenotypic elements
(EBV genes, EBV DNA copy number and intrinsic
growth rate). We also tested if the genetic burden of the
LCLeQTL SNPs was associated with EBNA-1 IgG titres
in data collated from a large anti-EBNA1 GWAS [35]
using a linear mixed-effects kinship model fit by max-
imum likelihood.
Genotyping and gene expression
In the Westmead LCL cohort, CD40 (SNP rs1883832)
and TRAF3 (SNPs rs12588969, rs12148050) were geno-
typed using Taqman Assays, and gene expression was
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assayed using Taqman probes Hs00912657_m1,
Hs00936778_m1 respectively (Life Technologies). Splicing
of CD40 was determined as previously described [36].
CD40 proliferation
For proliferation readout for the Westmead LCL co-
hort, LCLs were first labelled with Cell Trace Violet
(CTV, Life Technologies) at a final concentration of 5
mM. 5 × 104 LCLs were cultured with or without
CD40L (250 ng/mL, Adipogen) in 5-mL polystyrene
tubes (Becton Dickinson, BD) for 5 days. Day 5 cells
were harvested and ran on FACSCantoII flow cyt-
ometer (BD). Median fluorescence intensity (MFI) of
CTV was analysed using FlowJo.
Statistics
Analysis of gene expression differences in the WIMR LCL
and B cell cohort was conducted using GraphPad Prism 7
(GraphPad Software, USA) using paired and unpaired
(where appropriate) two-tailed T tests to compare between
groups. P values for overlaps were calculated using the
hypergeometric distribution over-representation test [37].
Results
The LCL transcriptome
To identify MS risk genes likely to contribute to vari-
ation in regulation of EBV infection, we first screened
for risk genes with altered regulation in EBV-infected B
cells (LCLs) compared to B cells. We used RNAseq to
interrogate expression in ex vivo CD19+ B cells and in
LCLs derived from them using EBV strain B95.8 infec-
tion. Consistent with their different phenotypes, the
transcriptomes were very different between infected and
uninfected B cells. At a false discovery rate (FDR) of
0.01, 8962 genes were expressed differently (Fig. 1)
(Additional file 1: Table S1). Differentially expressed
genes were enriched for interferon stimulated genes
(p < 0.001, Fig. 1c).
MS risk genes that are LCL eQTLs
Since risk SNPs mainly affects pathogenesis by altering
gene expression [16], we identified SNPs associated with
gene expression (expression quantitative trait loci;
eQTLs) in LCLs. We identified that of 255 MS risk
SNP:gene pairs, 47 were eQTLs in LCLs at p < 0.05 in
the GTEx dataset. This list of 47 SNP:gene pairs which
contains 44 SNPs and 47 genes we call LCLeQTL
(Additional file 1: Table S2). Using GTEx data as a dis-
covery dataset, and the RTeQTL data [38] as a replica-
tion set, of the 47 GTEx LCLeQTL SNP:gene pairs, 31
were tested in at least one of the RTeQTL cohorts, and
28 of these were replicated at p < 0.05, mostly with much
lower p values (Additional file 1: Table S3). We then
identified those 47 GTEx LCLeQTL SNP:gene pairs
more associated with expression in LCLs than whole
blood, as this would favour LCL expression as driving
the pathogenic basis for their association with MS, more
than expression in the immune cells of the blood (Fig. 2).
As the statistical power for the whole blood cohort was
greater, we based this comparison on rank of p value,
rather than raw p values. Of these, 18 had the same
genotype effect on expression in LCLs and whole blood,
17 of these had opposite genotype associations with ex-
pression. Finally, two did not have lower p values in
LCLs, but are included in the list as having opposite
genotype effects between LCLs and whole blood. This
list of 37 SNP:gene pairs which contains 35 SNPs and 37
genes, we call the LCLeQTL* (Additional file 1: Table
S4). Thirty-three of 47 LCLeQTL genes were in the
genes differentially expressed between B cells and LCLs
Fig. 1 RNAseq reveals vast gene expression changes in LCLs compared to CD19+B cells. a Scatter plot highlighting genes differentially expressed
at 1% FDR (red), b Genes proximal to MS risk SNPs are over-represented in the differentially expressed genes (hypergeometric over-representation
test), c Gene Set Enrichment Analysis (GSEA) shows interferon stimulated genes are over-represented in genes upregulated in LCLs
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(over-representation p = 1.53 × 10−4), and 24/37 of the
LCLeQTL* genes (p < 0.003, Fig. 3). Of the WBeQTLs (MS
risk SNP:gene pairs in eQTL in whole blood at p < 0.05)
(Additional file 1: Table S5), a lower proportion were in the
differentially expressed gene list (35/57, p < 0.004), even less
with the LCLeQTL* genes removed from the WBeQTL list
(Additional file 1: Table S6, 28/47, p < 0.017). Of the 255
MS risk genes, 139 were differentially expressed between
LCL and B cells (p < 1.44 × 10−4).
Despite these over-representations of LCLeQTL,
LCLeQTL*, WBeQTL SNPs and especially MS risk
genes in the genes differentially expressed between
EBV-infected and B cells, it remains possible that the en-
richment may point to the B cell functions of these
genes/SNPs rather than viral contribution to pathogen-
esis. We compared genes differently expressed between
B cells and activated B cells at FDR of 0.001 from pub-
lished data [27]. Of the 1474 genes differentially
expressed, 38 were MS risk genes (over-representation p
value 2.47 × 10−6), 6 were LCLeQTL genes (over-repre-
sentation p value 0.12) and 6 were LCLeQTL* genes
(over-representation p value 0.046). However, 1992
genes were differentially expressed at this FDR between
B cells and LCLs, 49 were MS risk genes (over-represen-
tation p value 2.59 × 10−7), 11 were LCLeQTL genes
(over-representation p value 0.0046) and 9 were
LCLeQTL* genes (over-representation p value 0.0074).
This suggests the MS risk genes, particularly LCLeQTL*
genes, are more dysregulated in LCLs than activated B
cells compared to B cells, implicating their role in EBV
infection is more important than in B cell activation.
MS risk genes potentially regulated by EBV transcription
factors
Harley et al. [11] and Ricigliano et al. [12] have identified
an excess of EBNA2 binding sites among risk SNPs for
MS and other autoimmune diseases. To identify
EBV-specific enrichment, we sought risk SNPs/genes
co-located with EBV transcription factor binding peaks
with the expanded set of MS risk SNPs [16]. Of the
45,498 SNPs with listed associations in the GWAS
catalogue, 871 were co-located with an EBV transcrip-
tion factor (TF) binding site [11]. MS risk SNPs were
co-located (28 of 201 mapped) with EBV TF binding peaks
at an extraordinary level of enrichment (Additional file 1:
Table S7, p = 3.17 × 10−16). Of the 44 LCLeQTL SNPs, 6
were co-located with EBNA2 peaks (p = 1.83 × 10−4). Of
these 6 SNPs, 5 SNPs were also in the 35 LCLeQTL* SNP
list (p = 5.1 × 10−4). The proximal genes to these 5 SNPs
were TRAF3, RCOR1, TBX6, TNFAIP8, TNFRSF1A and
CLECL1.
Fig. 2 The effect of MS risk SNP genotype on expression of proximal genes in whole blood and LCLs. The GTEx eQTL dataset was first filtered for
MS risk SNPs, and SNP:gene pairs were then plotted for effect of genotype (restricted to the genes closest to the MS risk SNPs—the proximal
genes). SNP:gene pairs that were more strongly associated with expression in LCLs (coloured blue) and those with a different risk allele effect in
LCLs compared to whole blood, more significant in LCLs (red) or opposite slope in LCLs(green) were identified as LCLeQTL*
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MS risk genes on the LMP1/LMP2 Signalling pathways
Next, we mapped the LCLeQTL* genes on to the LMP1
and LMP2 signalling pathways (Fig. 4). The LMP1 path-
way was as defined previously [39], which overlaps the
CD40 pathway as described [40]. This pathway was con-
firmed and extended in the work of Li et al. [41], who
used nasopharyngeal tumour mutations, a semi-agnostic
approach, to define the pathway. The LMP2 pathway
was as defined in Cen and Longnecker [42], who
described its overlap with the B cell receptor (BCR)
signalling pathway. LCLeQTL* gene-encoded protein
TRAF3 binds directly to LMP1 and CD40; IgG domain
containing proteins (genes CLECL1, CD200R and
IL1DR) may bind or compete with LMP2/BCR. Mole-
cules one signalling node down from this affect sumoyla-
tion (SAE1) and NFKB activation via the BCR (MALT1
and BCL10). NFKB is activated by both LMP1 and
LMP2 pathways and, in turn, regulates genes control-
ling apoptosis (different roles for BCL10 and MALT1
than above; TNFRSF1, ZNF767P, NDFIPP1, CTSH,
TNFAIP8, MAP3K14), proliferation and differentiation
(IKZF1, SAE1). The LCLeQTL* transcription factor
BATF interacts directly with NFKB in LCLs [43], and
TNFRSF1A directly activates it [44]. The mTOR com-
plex is activated by both LMP1 and LMP2 and enables
the vast changes in energy production required for the
proliferating B cells in latency III [45]. The LCLeQTL*
genes regulating ATP are ADCY3, DDX6, MAPK1,
ALPK2, MAP3K14, SAE1, DLEU1 and TNFAIP8 (GO
annotation). Finally, the interferon pathway is dysregu-
lated in latency III by altering expression of transcrip-
tion factors such as IRF5, IRF7 and the STATs [46].
This may underpin the genetic associations with
expression seen for SP140 in LCLs, so that EBV con-
tributes to altered expression to dampen the IFN
response. Several LCLeQTL*s were transcription fac-
tors of undefined roles: ZNHIT3, TBX6, RCOR1,
ZFP36L2 and AFF1. These are likely to mediate some
of the global changes to B cell function on infection.
Also, several LCLeQTL*s had functions not readily at-
tributable to LMP1/LMP2 signalling, and for others,
their functions are largely unknown. Collectively, there
is strong support for LCLeQTL* genes affecting latency
III gene expression programs.
Fig. 3 Genes and pathways with a stronger association of expression in LCLs compared to whole blood. a Heat map showing expression level of
genes corresponding to the SNP:gene pairs that were more strongly associated with expression in LCLs compared to whole blood (LCLeQTL*) in
CD19+ B cells and LCLs. b Over-representation of pathways and networks in LCLeQTL*(MSRG eQTLs in LCL (p < 0.05) with stronger/opposite
effect than in whole blood); LCLeQTL(MSRG eQTLs in LCL (p < 0.05)); WB eQTL minus LCLeQTL*(MSRG eQTL in whole blood (p < 0.05) minus
MSRG eQTLs in LCL (p < 0.05) with stronger/opposite effect than in whole blood); genes dysregulated in LCLs vs CD19+ B cells at 1% FDR; MSRG
with EBV transcription factor binding sites; MSRG, genes proximal to MS risk SNPs. TF, transcription factor. P values were calculated using
MetaCore (Clarivate Analytics)
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LCLeQTL genomic burden and EBV phenotype in vitro and
in vivo
The effect of risk alleles on regulation of EBV infection
and MS is likely to be complex, affecting LCL growth
rates, states and immune responses to infected lympho-
cytes in vivo. We tested the hypothesis that specific risk
alleles, and increasing genetic load of all LCLeQTL risk
alleles, would favour increased proliferation of infected B
cells. This may be detectable as increased intrinsic
growth rate of LCLs [31], increased expression of EBV
genes in LCLs, or increased EBV copy number in LCLs,
or, albeit with many checkpoints in between, increased
titre of anti EBNA1 antibodies. We first tested if each of
these LCL EBV phenotypes, intrinsic growth rate, ex-
pression levels of EBV latency III genes (EBNA2, LMP1)
and EBV DNA copy number in LCLs was correlated. In-
trinsic growth rate was available for LCLs from 92 indi-
viduals [31]. The gene expression data for EBV from the
same LCL samples was available on the EBV portal in
these LCLs [32]. Also, estimated EBV DNA copy num-
ber in the same LCL samples was obtained [34]. Intrinsic
growth rate and expression of EBV genes EBNA2 and
LMP1 were positively correlated; EBV copy number was
negatively correlated with these genes (Fig. 5). We were
surprised to find an inverse relationship between intrin-
sic growth rate and EBV DNA copy number in LCLs
(Additional file 2: Figure S4A, Additional file 1: Table S8).
Overall, LCLeQTL risk allele genetic burden was slightly
negatively correlated with LMP1 and EBNA2 expression
(Fig. 5 E and F, Additional file 1: Table S9) and intrinsic
growth rate (Additional file 2: Figure S4B, Additional file 1:
Table S10). A possible explanation for this is that the risk
alleles could be contributing to EBV immune evasion in a
myriad of ways in vivo, so that their net effect in vitro
(LCLs) may represent an artifactual balance. For example,
we tested particular genes sets from our model in Fig. 4
and found most of the negative association with intrinsic
growth rate/EBNA2 and LMP1 expression was due to
the genes affecting energy usage (Additional file 2:
Figure S4C, D). The risk alleles were associated with
slower growth rate, potentially indicating a less im-
munogenic LCL. Alternatively, this may indicate re-
duced capability of the immune response independently
of effect in LCLs and less control of EBV by this mech-
anism. Further, reduced proliferation of LCLs may cor-
respond to an altered balance in EBV cycling, with
Fig. 4 Model of LCLeQTL* gene roles in Latency III signalling pathways. Signalling from EBV proteins LMP1 and LMP2 leads to upregulation of
NFKB, sumoylation, and mTOR1 pathways and altered IFN regulation. LCLeQTL* genes with roles on these pathways are in red. Signalling from
the LMP1 homologue and MS risk gene CD40 inhibits LMP1 function (see Fig. 1). For similar reasons, signalling through the BCR, in this model,
blocks LMP2 pathways. Arrows indicate proposed effect of signalling through LMP1/LMP2 on each of the downstream processes
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more lytic phase production. The reverse correlation
between the LCL intrinsic growth rate and EBV copy
number in LCLs is consistent with this hypothesis,
since EBV copy number likely increases prior to lytic
phase initiation. No significant correlation was de-
tected between genetic burden and antiEBNA1 titres,
although low correlation was seen for some SNPs
(Additional file 1: Table S11). Again, it is difficult to
determine the significance of this, given the multiple
factors affecting this parameter.
CD40 and TRAF3 expression and risk genotype in B cells
and LCLs
Expression of CD40 is highest for the protective geno-
type (SNP rs1883832 T) in blood [19] and B cells [36].
We hypothesised this higher expression decreased sig-
nalling through LMP1 through competition for the same
signalling molecules. We first confirmed that its expres-
sion was higher in LCLs in GTEx data [47] for whole
blood (n = 396, p < 10−8, rank of p value 29/4566 genes)
and LCLs (n = 117, p < 0.06, rank 330/4566), and in the
RTeQTL data [38] (n = 955, combined p < 10−8 for GTEx
and RTeQTL data). Earlier, we had shown that the pro-
tective allele decreases mRNA encoding secreted CD40
(sCD40, exon 6 spliced out) in B cells and dendritic cells
[36]. In our LCL cohort (Westmead Institute for Medical
Research; WIMR LCLs), the full-length isoforms make
up 80% of transcripts, whereas they are only 65% of
transcripts in B cells (p < 10−9, Fig. 6a, b, Additional file 2:
Figure S5). Isoform usage was genotype independent in
both cell types. We then tested if signalling through
CD40 reduced LCL proliferation by culture with/without
CD40L. We found that proliferation of LCLs in the
presence of CD40L is decreased (p < 0.0001, Fig. 6c,
Additional file 2: Figure S6–7), with more inhibition for
the protective genotype (p < 0.03, Fig. 6d). This is con-
sistent with the CD40 protective genotype effect on MS
being due to reduced susceptibility to Latency III prolif-
eration of EBV.
TRAF3 is an MS risk gene with two independent asso-
ciation signals, for SNPs rs12588969 and rs12147246
[16]. TRAF3 protein binds to the CTAR1 domain of
LMP1 and reduces signalling through TRAF6, which
binds to the CTAR2 domain of LMP1 (see Fig. 4). We
found that the protective variant of the risk SNP
rs12588969 is associated with lower expression of
TRAF3 in GTEx LCLs (p < 0.0001) and in WIMR B cells,
with a trend in LCLs (Fig. 7), and replicated in the
RTeQTL dataset (combined p < 10−15), but not in blood.
This SNP is in a locus bound by the EBV transcription
factor EBNA2 (Fig. 7a). The protective allele of the sec-
ond SNP rs12147246 (using SNP rs12148050 as a proxy
SNP) was associated with higher expression of TRAF3
in B cells and in blood, but not in GTEx or WIMR
LCLs. The protective SNP of rs12148050 was associated
with reduced proliferation of LCLs in the presence of
Fig. 5 Genetic burden and EBV phenotypes. The correlation of LCL intrinsic growth rate with EBNA2 (a) and LMP1 (b) expression level in LCLs
(Spearman’s rank correlation). Correlation of EBV DNA copy number with EBNA2 (c) and LMP1 (d) expression level in LCLs (Spearman’s rank
correlation). Association of LCLeQTL genetic load (sum of risk alleles across all LCLeQTL SNPs) with EBNA2 (e) and LMP1 (f) expression level in
LCLs (calculated using linear regression)
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CD40L (p = 0.02, Fig. 7d), but no association was seen
for rs12588969.
These data are consistent with both CD40 and TRAF3
rs12148050 protective SNPs reducing susceptibility to
EBV due to genotype effects in B cells and LCLs, confer-
ring protection through decreasing signalling through
the LMP1 pathways in newly infected B cells or LCLs.
However, the expression pattern for rs12588969 is in-
consistent with this. The complexity of these findings
for TRAF3 may be due to different isoform usage, use of
the NFKB alternative pathway, or context-dependent
function in B and LCLs.
Finally, TRAF3 and CD40 risk SNPs are co-localised
with EBNA2 Chip-Seq peaks (Figs. 6 and 7), as are the
risk SNPs for four other LCLeQTLs. Consistent with an
EBNA2 effect on their expression, we now show that the
expression of TRAF3, CD40, TBX6, RCOR1 and
CLECL1 in LCLs is correlated with EBNA2 expression,
dependent in each case on the risk/protective genotype
(Fig. 8, Additional file 2: Figure S8–9). For TRAF3, those
with the risk allele targeted by EBNA2 (rs12588969) ex-
pression was lower when EBNA2 expression was higher
(Fig. 8b), consistent with lower expression of this gene
for risk allele (Fig. 7), and resultant reduced inhibition
LMP1 signalling. Similarly, the protective allele of
CD40 has higher expression when EBNA2 expression
is lower, consistent with higher expression inhibiting
LMP1 signalling. The CD40/TRAF3 risk allele genetic
load is negatively correlated with LMP1 expression
(Additional file 2: Figure S10).
Discussion
We sought evidence that response to EBV latency III in-
fection contributed to MS susceptibility from the re-
cently expanded list of MS risk loci [16]. The number of
MS risk SNPs associated with genes differentially
expressed between infected and uninfected B cells was
139 of 255, much more than would be expected by
chance. The number of MS risk SNPs where the geno-
type was associated with proximal gene expression (44
of the 201 risk SNPs) in LCLs was also much higher
than would be expected by chance. Thirty-five of these
44 were more associated with expression in LCLs than
they were with blood. EBV transcription factor binding
sites are over-represented among MS risk genes and
among LCLeQTLs, including at risk genotype sites for
Fig. 6 MS risk gene CD40 expression and signalling in B cells and LCLs. a Risk SNP rs1883832 is a binding site for the EBV transcription factor
EBNA2. b The proportion of full length CD40 mRNA is higher in LCLs compared to CD19+ B cells, independent of rs1883832 genotype. c CD40L
inhibits LCL proliferation (d) The inhibitory effect of CD40L on LCL proliferation is greater for the protective genotype (CC). Difference in
proliferation (Y axis) is the difference in proliferation of LCLs over 5 days cultured with or without CD40L, measured by median fluorescence
intensity of cell trace violet. * < 0.05,*** < 0.001, **** < 0.0001
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Fig. 7 The effect of MS risk SNP genotype on the expression of TRAF3. a Risk SNP rs12588969 is a binding site for the EBV transcription factor
EBNA2. The inhibitory effect of CD40L on LCL proliferation is greater for the protective genotype (GG) of rs1214050 (b). Difference in proliferation
(Y axis) is the difference in proliferation of LCLs over 5 days cultured with or without CD40L, measured by median fluorescence intensity of cell
trace violet. TRAF3 expression is genotype dependent in CD19+B cells for MS risk SNPs rs12147246 (measured by proxy SNP rs1214050) (c) and
rs12588969 (d). * < 0.05, ***, < 0.001
Fig. 8 Effect of genotype on the expression ratio of EBNA2 with MS risk genes. a EBNA2/CD40, (b) EBNA2/TBX6, (c) EBNA2/TRAF3 and (d) EBNA2/
RCOR1. Genotype effect on expression ratio was calculated using linear regression. Dotted line is regression slope, bars are mean + SEM. RR,
homozygous risk genotype, Het, heterozygote, PP, homozygous protective genotype
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six genes. Expression of five of these genes was associ-
ated with EBNA2 expression in LCLs dependent on
genotype, including CD40 and TRAF3. Expression of the
EBV LMP1 homologue CD40, and the LMP1 ligand
TRAF3, was affected by risk genotype in EBV-infected
cells and/or B cells. Infected B cell proliferation was re-
duced on signalling through CD40, and more so for the
protective genotypes of CD40 and TRAF3. The 37 MS
risk genes identified as LCLeQTL* have plausible roles
in signalling on the LMP1 and LMP2 pathways in EBV
latency III. The total genetic burden of LCLeQTL risk
alleles was negatively correlated with intrinsic growth
rate and EBV gene expression in LCLs. No correlation
between genetic burden and serum antiEBNA1 antibody
titres was detected.
Although these data provide genetic evidence that
EBV has a facilitative role in MS, they are not conclu-
sive. The association of MS risk genotypes with LCL ex-
pression, and the enrichment of risk genes involved in B
cell proliferation and utilised by EBV, may be due to B
cell processes contributing to disease, and independent
of the role in EBV latency III. Notably though, we found
the LCLeQTL genes were more dysregulated between
LCLs and unstimulated B cells than between activated B
cells and unstimulated B cells. Also, even though the
interaction between CD40/TRAF3/LMP1 would predict
protective genotypes decrease EBV latency III prolifera-
tion, this proliferation may be independent of the patho-
genic effect in MS of these genes. Finally, the association
of MS risk SNPs with expression and LCL proliferation
may be different in B cells from people with MS. It
should be noted that the MS risk SNPs are those affect-
ing susceptibility to MS, so they should be associated
with processes affecting pathogenesis. LCLs obtained
from those who have already developed disease may
have a phenotype representing disease state rather than
susceptibility. Consequently, control samples may be
more useful for detecting effects of risk SNPs on
pathogenesis.
Genes affecting MS susceptibility favour processes
leading to dysregulated immune responses, and if the
processes are ongoing and drive MS pathogenesis, re-
versing these would be expected halt progression.
Monoclonal antibodies to risk gene IL2Ra (drug Daclizu-
mab) and to CD49D, ligand of risk gene VLA4 (drug
Natalizumab), are effective therapies for MS [2]. More
generally, drugs which remove immune cells expressing
risk genes, such as antiCD20 (B cells) and antiCD52
(Alemtuzumab), or which corral them in secondary
lymphoid organs (Fingolimod) are also effective.
Similarly, if poor regulation of EBV infection contrib-
utes to MS susceptibility and progression via processes
tagged by the MS risk gene LCLeQTLs, therapeutic
strategies to favour immune control of EBV may halt or
slow progression. Especially attractive are targets on the
EBV genome, since these greatly increase specificity for
EBV compared to the host genes which regulate LMP1
and LMP2 signalling. Of these EBV targets, methods of
reducing EBNA2 expression or activation through its
binding partners are in development for other condi-
tions. Farrell et al. [48] have shown a cell-permeable
peptide inhibiting EBNA2 binding to co-transcription
factor CBF1 results in downregulation of EBV proteins
LMP1 and LMP2 and reduced LCL proliferation.
EBNA2 and other EBV transcription factors could be
inactivated with complementary nucleic acid therapeu-
tics, as currently used for familial amyloidotic polyneur-
opathy [49].
Although it is challenging to prove the MS risk geno-
type is associated with MS because it alters Latency III
proliferation and immune evasion, further support
would come from demonstrating [1] that reduction of
EBNA2 and targeted EBV (B95.8 strain) miRNAs reduce
the genotype association with expression in LCLs [2];
altered expression of the risk gene corresponding to the
LCLeQTL effect alters LCL proliferation, especially
through the pathway the gene affects; and [3] effects
may be exaggerated in LCLs derived from MS patients.
Testing of genotype effects on expression and function
in other EBV phases is also warranted. Finally, the killing
of LCLs by EBV-specific T cells or NK cells in co-cul-
tures may be risk genotype and gene dependent.
Conclusions
These data indicate many genetic risk factors identified
in genome wide association studies for MS susceptibility
have roles consistent with a dysregulated response to
EBV infection, and so in this way contribute to MS
pathogenesis. They point to particular molecular
processes important in regulating LCL proliferation, and
so molecular targets for control of EBV infection to po-
tentially reduce MS progression. Specifically, these data
indicate targeting EBV EBNA2, and MS risk genes func-
tioning on the LMP1/2 pathways, and the pathways
themselves, may be of therapeutic benefit in MS.
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S7. Cell trace violet dilution on CD40L stimulation for CD40 rs1883832
genotype. Figure S8. Effect of genotype on the expression ratio of
EBNA2 with MS risk genes. (A) EBNA2/CLECL1, (B) EBNA2/TNFRSF1A, (C)
EBNA2/TNFAIP8. Figure S9. The correlation between EBNA2 and
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SNP is co-located in EBNA2 binding peaks. Figure S10. LMP-1 expression
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